Raut, C. P., Espat, N. J., Maki, R. G., Araujo, D. M., Trent, J., Williams, T. F., . . . DeMatteo, R. P. (2018). Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial. JAMA Oncol.

Raut, Chandrajit P., N. Joseph Espat, Robert G. Maki, Dejka M. Araujo, Jonathan Trent, Toni Faith Williams, D. Das Purkayastha, ja Ronald P. DeMatteo. "Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial." JAMA Oncol 2018.

Raut, Chandrajit P., et al. "Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial." JAMA Oncol 2018.